60 degrees pharmaceuticals, Inc. Stock Price, News & Analysis

Welcome to our dedicated page for 60 degrees pharmaceuticals news (Ticker: SXTP), a resource for investors and traders seeking the latest updates and insights on 60 degrees pharmaceuticals stock.

News about 60 Degrees Pharmaceuticals, Inc. (SXTP) centers on its work in vector-borne diseases and the commercial performance of its lead antimalarial product, ARAKODAae (tafenoquine). Company announcements describe 60 Degrees Pharmaceuticals, Inc. as a pharmaceutical company focused on developing new medicines for vector-borne disease, with an FDA-approved product for malaria prophylaxis and multiple ongoing clinical programs.

Investors following SXTP news can read about updates on ARAKODA commercial activities, such as sales and marketing initiatives and pharmacy delivery trends, as well as information on clinical research in babesiosis. The company regularly reports milestones for its babesiosis trials, including the B-FREE Chronic Babesiosis Study, a Phase 2 open-label trial evaluating the ARAKODA regimen of tafenoquine over 90 days in patients with chronic babesiosis, and expanded access and randomized studies in hospitalized or high-risk patients with babesiosis.

News releases also highlight scientific collaborations and sponsored research, such as agreements with academic institutions to study tafenoquine against Babesia parasites and other pathogens associated with tick-borne illness. In addition, regulatory and corporate developments appear in the news flow, including disclosures about a reverse stock split intended to help maintain Nasdaq listing requirements and shareholder voting outcomes reported in SEC filings.

By reviewing the SXTP news feed, readers can track how 60 Degrees Pharmaceuticals, Inc. communicates progress on its malaria prophylaxis business, its vector-borne disease research pipeline, and key corporate actions affecting its Nasdaq-listed common stock and warrants. This page brings together these updates in one place for those monitoring the companys activities and public disclosures.